These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 14692714)

  • 21. Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer.
    van Zandwijk N; ten Bokkel Huinink WW; Wanders J; Simonetti G; Dubbelman R; Franklin H; van Tinteren H; McVie JG
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):16-9. PubMed ID: 2154854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.
    Bokemeyer C; Schmoll HJ; Ludwig E; Harstrick A; Dunn T; Casper J
    Br J Cancer; 1994 May; 69(5):863-7. PubMed ID: 8180015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
    Pendyala L; Schwartz G; Smith P; Zdanowicz J; Murphy M; Hausheer F
    Cancer Chemother Pharmacol; 2003 May; 51(5):376-84. PubMed ID: 12682786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Antman KH; Elias A; Ryan L
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuously improving ifosfamide/mesna: a winning combination.
    Anderson P
    Pediatr Blood Cancer; 2010 Oct; 55(4):599-600. PubMed ID: 20589648
    [No Abstract]   [Full Text] [Related]  

  • 26. Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study.
    Baur M; Fazeny-Doerner B; Hudec M; Sevelda P; Salzer H; Dittrich C
    Cancer Invest; 2006 Feb; 24(1):22-7. PubMed ID: 16466988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
    Schuchter LM; Hensley ML; Meropol NJ; Winer EP;
    J Clin Oncol; 2002 Jun; 20(12):2895-903. PubMed ID: 12065567
    [No Abstract]   [Full Text] [Related]  

  • 28. Malignant fibrous histiocytoma of the fallopian tube.
    Halligan AW; McGuinness EP
    Br J Obstet Gynaecol; 1990 Mar; 97(3):275-6. PubMed ID: 2159318
    [No Abstract]   [Full Text] [Related]  

  • 29. Oral administration of mesna with ifosfamide.
    Goren MP
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):91-6. PubMed ID: 8677457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
    J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.
    Verschraagen M; Boven E; Torun E; Erkelens CA; Hausheer FH; van der Vijgh WJ
    Br J Cancer; 2004 Apr; 90(8):1654-9. PubMed ID: 15083199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.
    Lind MJ; Gumbrell L; Cantwell BM; Millward MJ; Simmonds D; Proctor M; Chapman F; McCann E; Middleton I; Calvert AH
    Br J Cancer; 1995 Mar; 71(3):610-3. PubMed ID: 7533518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
    Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
    Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitomycin, ifosfamide, and mesna in the treatment of lung cancer.
    Dorr RT
    Semin Oncol; 1990 Aug; 17(4 Suppl 7):2-5. PubMed ID: 2116668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study.
    Cervellino JC; Araujo CE; Pirisi C; Francia A; Cerruti R
    Oncology; 1991; 48(2):89-92. PubMed ID: 1900124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An unusual case of haematuria.
    Cassidy J; Kaye SB
    Eur J Cancer; 1993; 29A(6):906-7. PubMed ID: 8387321
    [No Abstract]   [Full Text] [Related]  

  • 37. Prophylaxis with mesna prevents oxidative stress induced by ischemia reperfusion in the intestine via inhibition of nuclear factor-kappaB activation.
    Ypsilantis P; Tentes I; Lambropoulou M; Anagnostopoulos K; Papadopoulos N; Kortsaris A; Simopoulos C
    J Gastroenterol Hepatol; 2008 Feb; 23(2):328-35. PubMed ID: 17868332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus granulocyte-colony stimulating factor in advanced non small cell lung cancer.
    Tognoni A; Cadenotti L; Pensa F; Vaira F; Vigani A; Bancalari L; Cordani S; Maggiani R; Canessa PA; Pronzato P
    J Chemother; 1999 Aug; 11(4):306-9. PubMed ID: 10465134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide.
    Khaw SL; Downie PA; Waters KD; Ashley DM; Heath JA
    Pediatr Blood Cancer; 2007 Sep; 49(3):341-3. PubMed ID: 16333822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MINE-ESHAP salvage therapy for recurrent and refractory lymphomas.
    Cabanillas F; Rodriguez MA
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):30. PubMed ID: 8073305
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.